1、1Financing environment of biopharmaceutical SMEs in EuropeSurvey ResultsJune 20232Survey focusing on the financing environment of biopharmaceutical SMEs in EuropeSurvey period:November 2021 to July 2022Objectives:Small European biopharmaceutical companies operating in Europe were surveyed in order t

2、o map the financial environment they are evolving in.The outcomes of the survey will help raise awareness among European decision makers about numerous obstacles that small companies are facing in Europe and that are hampering innovation.It will also help propose solutions to enhance the European bi

3、opharmaceutical funding ecosystem for SMEs and small mid-caps(public and private).Method:Polled online,available on LinkedIn and Twitter,sent to EMA registered SMEs and national trade associationsFeedback received from 43 SMEsSurvey background3PART I-RESPONDERS PROFILES4Presentation of profiles whic

4、h responded:Demographics 53%of responses are from CEOsMost of responses represent Nordic and Western European biotech SMEs90%of responses are SMEs of 5 years70%14%16%Licensing the rightsCommercialising on your ownUndecided2/3 would licence their rights and not commercialise on their own7Presentation

5、 of profiles which responded:Capital structures16%are listed companies84%are privately owned*Ownership type:wording used in the surveyHigh level of control/Low liquidity,e.g:small group holding 50%High level of control/High liquidity,e.g:single owner holding 20%Low level of control/High liquidity,e.

6、g:fragmented ownership with no holding 5%Ownership is concentrated among a single(1/3)or a small group(1/3)of owners,retaining high control of the companyControl HIGHLiquidity LOWControl HIGHLiquidity HIGHControl LOWLiquidity HIGHOther0%10%20%30%40%*8Main findings9PART II FINANCING:SITUATION AND OPP